American College of Cardiology/American Heart Association (ACC/AHA) guidelines for treatment of hypertension were last published in 2018.1 Treatment of hypertensive urgencies and emergencies is not discussed here.
NONPHARMACOLOGIC INTERVENTIONS — Adoption of a heart-healthy diet such as the Dietary Approaches to Stop Hypertension (DASH) diet,2 limiting intake of sodium (ideally...
- Sotatercept (Winrevair) for Pulmonary Arterial Hypertension
- A New Indication for Bempedoic Acid (Nexletol)
- Sarilumab (Kevzara) for Polymyalgia Rheumatica
- In Brief: Casgevy for Beta Thalassemia
- COVID-19 Update: An EUA for Pemivibart (Pemgarda) for Pre-Exposure Prophylaxis
- Eflornithine (Iwilfin) for High-Risk Neuroblastoma (online only)
- Erdafitinib (Balversa) for Urothelial Carcinoma (online only)
- Tislelizumab (Tevimbra) for Esophageal Cancer (online only)
RELEASE
Efbemalenograstim alfa-vuxw (Ryzneuta – Evive), a nonpegylated granulocyte colony-stimulating factor (G-CSF) conjugated to an Fc fragment of human IgG2, has been approved by the FDA to decrease the incidence of infection, as manifested by febrile neutropenia, in adults with nonmyeloid malignancies receiving myelosuppressive chemotherapy that can cause clinically significant febrile neutropenia. It is the first nonpegylated, long-acting G-CSF to become available in the US. Two pegylated, long-acting G-CSFs, pegfilgrastim (Neulasta, and biosimilars) and eflapegrastim (Rolvedon), are also available.
RECOMBINANT G-CSF ― Like other G-CSFs, efbemalenograstim alfa binds to G-CSF receptors on hematopoietic cells, stimulating neutrophil proliferation, differentiation, commitment, and activity. GCSFs decrease the duration …